Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months...

|By:, SA News Editor

Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months after commercial marketing began. Bloomberg's Andrew Berens says the company will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75, which is 70% below the current price. The move could pose risks for Arena's (ARNA -4.4%) Belviq, which is a competitor to Qsymia.